BioSpace News Archive

Select Medical Holdings Corporation (“Select Medical”) (NYSE: SEM) today announced results for its second quarter ended June 30, 2019.

Signant Health (formerly CRF Health and Bracket) today announces that its Senior Vice President, Dr. David Daniel, has been selected by PharmaVOICE as one of the top 100 most inspiring people within the life sciences sector.

In the largest life sciences lease in the City of Boston since 2011, WS Development today announced that Foundation Medicine has leased 580,000 square feet of laboratory and office space at 400 Summer Street, part of the company’s 23-acre Boston Seaport development, a joint venture with PSP Investments.

BioReference Laboratories, Inc., one of the largest clinical laboratories in the United States, today announced it has been selected by The IPA Association of America (TIPAAA) as its preferred provider of laboratory services and to assist with data analytics for its members’ patients.

Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), today announced that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved the clonoSEQ®Assay for the detection and monitoring of minimal residual disease (MRD) in patients with B-cell blood cancers

More than $2.45 Million Raised to Bring New Mobile STEM Labs to 300 Percent More Middle and High Schoolers in Maryland and Texas

An audio-visual feast of pharmaceuticals, a fortissimo in the pharmaceutical era of China

Advanced Instruments—an innovative developer of scientific and analytical instruments and related services for the biotech industry—announced the latest release to its biotech instrument portfolio, the OsmoTECH PRO Multi-Sample Micro-Osmometer.

Rakuten Medical, Inc., a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, has raised approximately US $100 million on July 31, 2019, i

Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announced today that the first patient was dosed in study ABX464-301, a phase 2a clinical trial of ABX464 to treat patients with moderate to severe active rheumatoid arthritis (RA).